PURPOSE: To investigate the effects of vitreomacular traction (VMT) on ranibizumab treatment response for neovascular @entity1020 ( @entity1020 ). METHODS: A retrospective review of 85 eyes of 85 @entity1 newly diagnosed with neovascular @entity1020 was conducted. @entity1 were eligible if they had received more than three consecutive monthly ranibizumab (0.50 mg) treatments and ophthalmic evaluations. @entity1 were classified into a VMT (+) group or VMT (-) group according to optical coherence tomography imaging. Best corrected visual acuity and central retinal thickness (CRT) measurements were obtained at three and six months after initial injection. RESULTS: One month after the third injection, mean visual acuity (VA) increases of 6.36 and 9.87 letters were observed in the VMT (+) and VMT (-) groups, respectively. The corresponding mean CRT values decreased by 70.29   m and 121.68   m, respectively. A total 41 eyes were identified as eligible for a subsequent fourth injection; 71.1% of @entity1 (27 eyes) in the VMT (+) group but only 29.8% of @entity1 in the VMT (-) group needed a subsequent fourth injection. Follow-up was extended to six months for 42 of the 85 enrolled @entity1 (49.4%). The trends in VA and optical coherence tomography were found to be maintained at six-month follow-up. CONCLUSIONS: VA and CRT appeared to be more improved after ranibizumab treatment in the VMT (-) group compared to the VMT (+) group. VMT might antagonize the effect of ranibizumab treatment in a subpopulation of @entity1020 @entity1 .

Effects of Vitreomacular Traction on Ranibizumab Treatment Response in Eyes with Neovascular Age-related XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['AMD', 'age-related macular degeneration']
@entity1020 :: (MESH:D008268,Disease) :: ['Macular Degeneration']
